Background Predicting drug pharmacokinetics in pregnant women including placental drug
transfer remains challenging. This study aimed to develop and evaluate maternal–fetal …

Abstract Background and Objective Little is understood about neonatal pharmacokinetics
immediately after delivery and during the first days of life following intrauterine exposure to …

Dolutegravir is currently recommended by the WHO as the preferred first-line treatment for
all people with HIV, including pregnant women. Estimates indicate that, by 2024, nearly 22 …

Antiretroviral therapy during pregnancy reduces the risk of vertical HIV‐1 transmission.
However, drug dosing is challenging as pharmacokinetics (PK) may be altered during …

Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy.
After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged …

Background Only a few antiretroviral drugs (ARVs) are recommended for use during the
neonatal period and there is a need for more to be approved to increase treatment and …

Background Fetal antiretroviral exposure is usually derived from the cord-to-maternal
concentration ratio. This static parameter does not provide information on the …

Pregnant women are usually excluded from clinical trials. Physiologically based
pharmacokinetic (PBPK) modelling may provide a method to predict pharmacokinetics in …

Aims Long‐acting cabotegravir and rilpivirine have been approved to manage HIV in adults,
but data regarding safe use in pregnancy are limited. Physiologically‐based …

The integrase inhibitors elvitegravir (EVG) and dolutegravir (DTG) rapidly decrease the
plasma HIV-1 viral load, a key factor in the prevention of maternal-to-fetal transmission of …